DailyWealth Investment Newsletter  

About DailyWealth Premium Content DailyWealth Archive
DailyWealth Investment Newsletter DailyWealth Contributors DailyWealth Resources DailyWealth Market Window
 
DailyWealth Print Edition Print Edition | Also Visit S&A Investment Research & Growth Stock Wire
True Wealth Login

Psst... Cheap Drugs Here...
by Dr. Steve Sjuggerud
May 2, 2006

The last time we saw drugs stocks so cheap, investors made nearly 500% gains…

From the bottom in 1994 - to the top in 1999 - the “boring” drug giants like Pfizer and Merck would have made you four times your money. But since that peak, drug stocks have been one of the world’s worst investments.

Fortunately, since the launch of my newsletter True Wealth in 2001, I’ve never bought a drug stock… I’ve never recommended a pharmaceutical company to my readers.

It’s been the right call… as pharmaceutical giants Pfizer and Merck have lost about half their value since 2001, as the chart below shows:

But for the first time ever, I’m getting much closer to buying them…

While drug stocks have lost investors money for the last five years, these companies are still selling more drugs. Sales at Pfizer, for example, have grown by more than 20% a year since 1996. And, unbelievably, Merck’s average annual profit margin in the past ten years has been 20%.

At some point, these stocks are going to look very cheap. I think we’re close…

---------- Advertisement ----------
The Secret Behind the World's Richest Family

What do rich people do when stocks and real estate get risky?

Many of the world's wealthiest families (such as the DuPonts, Morgans, Adams) use a secret form of currency, which was outlawed by the government for 41 years, but is now legal again.

In fact, this "Secret Currency" was the foundation of the richest family in world history.

Click here for report, which explains all the details... and details how you can use it to safely make a fortune today...
----------------------------------

Pfizer is a good example… the stock is 25 bucks - half of what it was in 1999. Yet analysts expect it will make $2 per share in profit this year… which means the stock is trading at a price-to-earnings ratio of only 12.5 (that’s $25 divided by $2). Pfizer also pays a big 4% dividend.

Why would you own a rental property now, when you can buy a stock like this with those kinds of numbers? If you’re a real estate guy, owning Pfizer shares would be like buying a house with an 8% NET rental yield (after expenses)… and that business will continue to grow.

Pfizer is an empire… Standard & Poor’s states it matter-of-factly in its latest research report:

“About 15 Pfizer drugs are the leaders in their respective therapeutic markets, five are among the world’s top selling products, and eight generate sales exceeding $1 billion a year. The company’s broad range of drugs reduces its dependence on any single product. Foreign sales accounted for 48% of total revenues in 2005.”

Pfizer’s size and financial strength are advantages, both in terms of making deals with smaller companies with drugs in development, and in dealing with Medicare. According to the S&P report, Pfizer has over 235 products in its pipeline.

I’m no expert in drug stocks… but what I love to buy is:

Assets of extraordinary value… that are cheap… where the uptrend is just beginning.

Major drug stocks are now looking cheap. We ran the numbers in house, and found that, relative to the overall stock market, drug stocks have only been cheaper one time in recorded history (going back to 1973). That time was in 1994.

If you had bought back then, and managed to sell at the top in 1999, you’d have made a profit of 500% in the big-name drug stocks alone. The smaller names were probably up many times that amount.

However…

It’s not time to buy just yet. The uptrend has not yet begun.

The thing about “value” stocks like these is, they can become even more of a “value” after you buy them. You could have said Merck was cheap any time in the last few years. Yet it’s only gotten cheaper…

That’s why I prefer to wait for the uptrend to show itself, and let the market tell me I’m right.

It can take years before an uptrend finally sets in. By waiting for the uptrend, I usually miss the first 20% of a move, of course. But if the move is going to be 500%, I’m all right with missing that.

The idea is, I’m entering the position in a low-risk way, and I’m not sitting on dead money for years, waiting for it to come to life.

I’m no expert in drug stocks. Far from it. But by my math, they’re as cheap as they’ve been relative to the market as any time in recorded history, except 1994.

Once the downtrend is broken - and the uptrend begins - you could make some real money. Chances are good I’ll be buying major drug stocks sometime in the next year or two in True Wealth.

Good investing,

Steve

In our February 10th edition, we highlighted the fall of St. Joe.

As one of the largest real estate developers in America, the St. Joe Company (JOE) is a $4 billion bellwether of publicly traded real estate stocks. With miles of Florida panhandle coastline, JOE owns 3% of the entire state.

With such large land holdings, JOE is one of DailyWealth’s favorite stocks to track the health of costal real estate. As JOE is trading at new 2006 lows, this health is in question.

If the stock market truly looks months ahead, this decline is not a good omen for Florida real estate…

Sliding down to the lower right… the fall of JOE (2-year chart):

-Brian Hunt


“Unlike for such commodities as corn, crude oil and copper, demand-side analysis cannot focus on the comparatively straightforward value of gold as an intermediate product in final products sold to consumers.

Ownership of gold by speculators has already reached a kind of critical mass. According to CPM's estimates, speculators now hold about 1.1 billion ounces. For the first time in history, they own more than is held by government central banks.”

-Gene Epstein, in Barron’s

“A new Bank of America report shows Africa provided more oil to the U.S. market in 2005 than the Middle East.

'Unbeknownst to many U.S. investors, America has become increasingly exposed to an unexpected or sudden drop in African oil production due to its greater reliance on African oil,' Joseph Quinlan, chief market strategist at Bank of America, writes in the April 20 report.

Quinlan notes that Iran's nuclear ambitions were not the only factor behind April's record oil prices, which closed Friday at $71.88 a barrel. The price increases also can be blamed on unrest in Nigeria's oil-producing Delta region. Bank of America's report put Nigeria at No. 5 — after Canada, Mexico, Saudi Arabia and Venezuela — on the list of top oil suppliers to the USA.

Imports of African oil reached 921 million barrels, or 18.7% of the U.S. total, in 2005, according to the Bank of America report. That surpassed imports from the Middle East, which were 839 million barrels, or 17%.”

-USA Today

"U.S. 801(k) Plans" better than 401(k)s and IRAs?

These secret "801(k) Plans"—which have no age, income, or employment requirements—pay up to 1,000% – 2,000% more than 401(k)s or IRAs.

But it's unlikely you've ever heard about these special programs before: The U.S. government doesn't allow them to be advertised to the general public.

Click here to find out more.

Have you heard of "U.S. 801(k) Plans?"

Don't be surprised if you've never heard about America's best-kept moneymaking secret...

I'm talking about "U.S. 801(k) Plans" which enable ordinary Americans to reliably collect huge sums of money—$50,000... $75,000... even $100,000 or more—beginning with as little as $25.

Marketwatch calls this opportunity "The best-kept secret on Wall Street."

Click here to learn more.

Ripple Trading An Oil Spike
May 01, 2006

The Best Plays on Gold... That You've Never Bought
April 28, 2006

The Contrarians Have Got It Wrong
April 27, 2006

Alexander’s Nuclear Potato Trade
April 26, 2006

Emerging Market Stocks: Why I’m
Cautious Now
April 25, 2006

Home | About DailyWealth | Premium Content | DailyWealth Archive | Contributors
DailyWealth Resources | Research Reports | Privacy Policy

Customer Service: 1-888-261-2693 – Copyright 2008 Stansberry & Associates Investment Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry & Associates Investment Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202